TITLE

After budesonide, what next for collagenous colitis?

AUTHOR(S)
Pardi, Darrell S.
PUB. DATE
January 2009
SOURCE
Gut;Jan2009, Vol. 58 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents studies assessing budesonide maintenance therapy in collagenous colitis in a randomized, placebo controlled fashion. Results of the first study confirms the efficacy of budesonide in all collagenous colitis. It also presents some side effects of budesonide that were potentially steroid-related. In a similar study, it assessed the efficacy of 6 mg/day maintenance dose, while in practice, clinicians typically continue to taper the dose of budesonide to lowest effective dose.
ACCESSION #
35965698

 

Related Articles

  • A Comparison of Mesalamine Suspension Enema and Oral Sulfasalazine for Treatment of Active Distal Ulcerative Colitis in Adults. Kam, Lori; Cohen, Hartley; Dooley, Cornelius; Rubin, Peter; Orchard, John // American Journal of Gastroenterology;Jul1996, Vol. 91 Issue 7, p1338 

    Objectives: To compare the efficacy and safety of mesalamine (5-ASA) suspension enema versus oral sulfasalazine (SAS) in patients with active mild to moderate distal ulcerative colitis. Methods: Thirty-seven patients were randomly assigned to treatment with either rectal mesalamine, 4 g...

  • Prednisolone.  // Reactions Weekly;1/22/2005, Issue 1035, p13 

    Discusses research being done on pseudotumour cerebri during treatment with prednisolone for ulcerative colitis. Reference to a study by J. M. Fonseca Chebli et al published in the October 2004 issue of the "Journal of Clinical Gastroenterology"; Side effects; Dosage of the drug received by the...

  • Double-Blind Placebo-Controlled Study of Olsalazine in the Treatment of Ulcerative Colitis. Zinberg, Jonathan; Molinas, Sharon; Das, Kiron M. // American Journal of Gastroenterology;May1990, Vol. 85 Issue 5, p562 

    Olsalazine is a compound consisting of two 5-amino salicylate (5-ASA) molecules linked by an azo bond, which, administered orally, is split by colonic bacteria to liberate 5-ASA. It lacks the sulfapyridine moiety found in sulfasalazine. Using a specific protocol, we conducted a randomized,...

  • Pre-existing Conditions, Placebo Reactions, and "Side Effects". Green, D.M. // Annals of Internal Medicine;Feb64 Part 2, Vol. 60 Issue 2, p255 

    Explores the possible relationship between pre-treatment conditions and placebo reactions and the subsequent appearance of symptoms that could be regarded as drug side effects. Adverse effects that may follow the giving of a presumed medication; Range of frequency in the reported symptoms;...

  • Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis. Sandborn, William J; Targan, Stephan R; Byers, Vera S; Rutty, Dean A; Mu, Hua; Zhang, Xun; Tang, Tom // American Journal of Gastroenterology;Jan2013, Vol. 108 Issue 1, p90 

    OBJECTIVES:Andrographis paniculata has in vitro inhibitory activity against TNF-α, IL-1β and NF-κB. A pilot study of A. paniculata extract (HMPL-004) suggested similar efficacy to mesalamine for ulcerative colitis.METHODS:A randomized, double-blind, placebo-controlled trial evaluated...

  • Mesalazine.  // Reactions Weekly;10/30/2010, Issue 1325, p22 

    The article describes the case of a 33-year-old man who acquired eosinophilic colitis while undergoing treatment with mesalazine.

  • Oxetorone.  // Reactions Weekly;5/8/2010, Issue 1300, p38 

    The article describes the case of a 34-year-old woman who developed lymphocytic colitis while receiving oxetorone therapy.

  • The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Vermeire, Séverine; Ghosh, Subrata; Panes, Julian; FDahlerup, Jens; Luegering, Andreas; Sirotiakova, Jana; Strauch, Ulrike; Burgess, Gary; Spanton, Jacqueline; WMartin, Steven; Niezychowski, Wojciech // Gut;Aug2011, Vol. 60 Issue 8, p1068 

    Background and aims: Leucocyte migration to gut mucosa, mediated by integrin binding to mucosal addressin cell adhesion molecule (MAdCAM), is a promising target for therapeutic intervention in inflammatory bowel disease. This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659,...

  • Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis. Zheng Yang; Xiao-Qing Ye; Yu-Zhen Zhu; Zhou Liu; Ying Zou; Ying Deng; Can-Can Guo; Garg, Sushil Kumar; Jin-Shan Feng // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 1, p86 

    Background: Adalimumab is used in an attempt to maintain remission for Ulcerative colitis. This study was to evaluate the efficacy and adverse events of adalimumab compared with placebo in inducing remission of Ulcerative colitis. Methods: MEDLINE, EMBASE, the Cochrane Controlled Trials...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics